immunoassay comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-04-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 4,700 Da | Peptide of roughly forty amino acids |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist class |
| Research code | LY3437943 | Internal development designation |
| Compound class | Incretin mimetic peptide | Synthetic, not a biologic extract |
| Development status | Investigational | No general regulatory approval |
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Research-grade peptide material is commonly supplied as a lyophilized powder, a form that limits degradation during transport and storage. Standard practice keeps such material cold and protected from light and moisture, with tighter conditions used for long-term archives. Once dissolved, solutions are generally considered less stable than the dry powder and are handled on shorter timescales. These established conventions derive largely from general peptide chemistry rather than from compound-specific evidence alone.
Identification and purity assessment typically rely on reversed-phase high-performance liquid chromatography, often paired with mass spectrometry. Mass measurement confirms the expected molecular mass and can reveal truncations or modifications. Peptide mapping and sequencing techniques provide sequence-level confirmation when needed. Because related peptide impurities can behave similarly in a single method, orthogonal techniques are usually combined. Reported purity values depend heavily on the method used and should be interpreted with that in mind.
A growing number of cases seek to enforce liability on gas, oil and coal polluters. In Friends of the Earth v Royal Dutch Shell plc, the Hague District Court held that Shell was bound by the tort provisions of the Dutch Civil Code, Book 6, section 162(2), interpreted in light of the Paris Agreement 2015 article 2(1) and ECHR articles 2 and 8 (rights to life and home), to immediately start cutting all of its emissions by 45% by 2030, whether generated directly by its corporate group (scope 1), indirectly from its purchases (scope 2), or indirectly from its value chain or the purchase and use of its products (scope 3). It emphasised the 'serious and irreversible consequences of dangerous climate change in the Netherlands... pose a threat to the human rights of Dutch residents'. After this loss, Shell dropped "Royal Dutch" from its name, and moved its headquarters to London. In Lliuya v RWE AG Mr Lliuya, who lives in Huaraz, Peru has claimed that RWE AG should pay 0.47% of the costs of flood defences against a melting mountain glacier that increases the size of Lake Palcacocha, because RWE is responsible for 0.47% of historic global greenhouse gas emissions. The Higher Regional Court of Essen gave leave to appeal on whether there is causation of damage, and in 2022 visited the lake. There has also been heightened responsibility on member state governments.
==== Racial equality ==== On 6 January, Lula signed into law a bill creating the Day of the Traditional African religions. Later, on 11 January, Lula signed in a bill that equalized the crime of "racial injury" to racism. On 21 March, the National Day to Combat Racial Discrimination, Lula signed the Racial Equality Bill, made up of seven measures, among which is the "Aquilomba Brasil" programme and the goal of having black people in at least 30% of commissioned positions and functions. On 21 December 2023, Lula sanctioned a bill approved in the deputies' chamber that turned the "Dia Nacional do Zumbi e da consciência negra" (black consciousness day) into a national holiday.
Difluoroescaline (DFE), also known as 4-(2,2-difluoroethoxy)-3,5-dimethoxyphenethylamine, is a psychedelic drug of the phenethylamine and scaline families related to mescaline. It is a difluorinated derivative of escaline. Its dose range is 40 to 80 mg and its duration is 6 to 12 hours. The drug's effects include color enhancement, some closed-eye and open-eye visuals, emotional changes, and some physical discomfort. It acts as a low-potency partial agonist of the serotonin 5-HT2A receptor and also interacts with other serotonin receptors and targets. The chemical synthesis of difluoroescaline has been described. Difluoroescaline was first described in the scientific literature by Daniel Trachsel in 2002. Its pharmacology was studied in more detail in 2021. It is not a controlled substance in Canada as of 2025.
== Occurrence == Uranium is a naturally occurring element found in low levels in all rock, soil, and water. It is the highest-numbered element found naturally in significant quantities on Earth and is almost always found combined with other elements. Uranium is the 48th most abundant element in the Earth's crust. The decay of uranium, thorium, and potassium-40 in Earth's mantle is thought to be the main source of heat that keeps the Earth's outer core in the liquid state and drives mantle convection, which in turn drives plate tectonics. Uranium's concentration in the Earth's crust is (depending on the reference) 2 to 4 parts per million, or about 40 times as abundant as silver. The Earth's crust from the surface to 25 km (15 mi) down is calculated to contain 1017 kg (2×1017 lb) of uranium while the oceans may contain 1013 kg (2×1013 lb). The concentration of uranium in soil ranges from 0.7 to 11 parts per million (up to 15 parts per million in farmland soil due to use of phosphate fertilizers containing uranium impurities), and its concentration in sea water is 3 parts per billion. Uranium is more plentiful than antimony, tin, cadmium, mercury, or silver, and it is about as abundant as arsenic or molybdenum. Uranium is found in hundreds of minerals, including:
=== Microfluidics === Microfluidics, in particular droplet microfluidics, is an emerging tool used to construct new components, and to analyze and characterize them. It is widely employed in screening assays.
Sources: en.wikipedia.org
== Women's rights == The Ba'athist regime in Syria discriminated against women through administrative measures that silenced their voices and through deploying political violence disproportionately against women. Sexual violence has long been a strategy of the regime to enforce the compliance of the populace. During the Syrian civil war, mass-rapes have been weaponized as a large-scale war-tactic by the Assad regime and the Ba'athist militant forces across Syria. Sexual violence against women on a political and sectarian basis has been described as a fundamental pillar of the regime's military strategy. Anti-Sunni Shabiha and other pro-Assad death squads carry out this policy on a sectarian basis, against Sunni women and girls. Many women suspected of pro-opposition sympathies are rounded up by Ba'athist paramilitaries and sexually assaulted in government detention centres and military prisons. Rural and poor women get disproportionately raped, assaulted, beaten and tortured in military prisons. Several women get abducted by dreaded Mukhabarat and raped in the offices of the secret police. According to many survivors, they can't return to their society without justice against the perpetrators.
== Treatment == Necrotizing fasciitis is treated with surgical debridement (cutting away affected tissue). However, antibiotics should be started as soon as this condition is suspected. Appropriate antibiotic coverage may change based on tissue cultures. Additional support should be initiated for those with unstable vital signs and low urine output.
Ultra-high vacuum chambers, common in chemistry, physics, and engineering, operate below one trillionth (10−12) of atmospheric pressure (100 nPa), and can reach around 100 particles/cm3. Outer space is an even higher-quality vacuum, with the equivalent of just a few hydrogen atoms per cubic meter on average in intergalactic space. Vacuum has been a frequent topic of philosophical debate since ancient Greek times, but was not studied empirically until the 17th century. Clemens Timpler (1605) philosophized about the experimental possibility of producing a vacuum in small tubes. Evangelista Torricelli produced the first laboratory vacuum in 1643, and other experimental techniques were developed as a result of his theories of atmospheric pressure. A Torricellian vacuum is created by filling with mercury a tall glass container closed at one end, and then inverting it in a bowl to contain the mercury (see below). Vacuum became a valuable industrial tool in the 20th century with the introduction of incandescent light bulbs and vacuum tubes, and a wide array of vacuum technologies has since become available. The development of human spaceflight has raised interest in the impact of vacuum on human health, and on life forms in general.
== Scientific analysis == Sindonology (from the Greek σινδών—sindon, the word used in the Gospel of Mark to describe the type of the burial cloth of Jesus) is the formal study of the Shroud. The Oxford English Dictionary cites the first use of this word in 1964: "The investigation ... assumed the stature of a separate discipline and was given a name, sindonology", but also identifies the use of "sindonological" in 1950 and "sindonologist" in 1953. Secondo Pia's 1898 photographs of the shroud allowed the scientific community to begin to study it. A variety of scientific theories regarding the shroud have since been proposed, based on disciplines ranging from chemistry to biology and medical forensics to optical image analysis. The scientific approaches to the study of the Shroud fall into three groups: material analysis (both chemical and historical), biology and medical forensics and image analysis.
Sources: en.wikipedia.org
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.
No regulatory agency has approved it for routine medical use. It remains an investigational compound studied in controlled trials. Access outside research settings is not established.
Each receptor influences energy balance through different pathways. Combining them is intended to add fat loss from lowered intake and higher expenditure. The optimal balance among the three effects is still under study.
Trials measure percentage change in body weight, absolute weight loss, and glycemic markers such as hemoglobin A1c. They also record blood pressure, lipids, and liver fat. Adverse events are tracked throughout.